{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disorder&page=54",
    "query": {
      "condition": "Retinal Disorder",
      "page": 54
    },
    "page_size": 10
  },
  "pagination": {
    "page": 54,
    "page_size": 10,
    "total_count": 1622,
    "total_pages": 163,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disorder&page=55&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disorder&page=53&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-10T07:50:20.490Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00027287",
      "title": "Laser and Medical Treatment of Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "Vitamin E",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 60,
      "start_date": "2001-11",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-11-10T07:50:20.490Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027287"
    },
    {
      "nct_id": "NCT00615693",
      "title": "Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uveitis",
        "Posterior Uveitis",
        "Panuveitis"
      ],
      "interventions": [
        {
          "name": "AEB071",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 13,
      "start_date": "2008-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-12-22",
      "last_synced_at": "2026-11-10T07:50:20.490Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00615693"
    },
    {
      "nct_id": "NCT07408232",
      "title": "A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "Phase 1b/2: Cohort 1 - OCT-980 Tablet",
          "type": "DRUG"
        },
        {
          "name": "Phase 1b/2: Cohort 2 - OCT-980 Tablet",
          "type": "DRUG"
        },
        {
          "name": "Phase 1b/2: Cohort 3 - OCT-980 Tablet",
          "type": "DRUG"
        },
        {
          "name": "Phase 1b/2: Cohort 4 - OCT-980 Tablet",
          "type": "DRUG"
        },
        {
          "name": "Phase 1b/2: Cohort 5 - OCT-980 Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octant, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2026-03-10",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-10T07:50:20.490Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon • Dallas, Texas",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07408232"
    },
    {
      "nct_id": "NCT01710332",
      "title": "The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Serous Chorioretinopathy"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-10",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-06-16",
      "last_synced_at": "2026-11-10T07:50:20.490Z",
      "location_count": 2,
      "location_summary": "Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Huntingdon Valley",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01710332"
    },
    {
      "nct_id": "NCT04035239",
      "title": "Retinal Effects of Balance Goggles System in Glaucoma Balance Goggles System (BGS) in Patients With Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "BGS goggles",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-07-23",
      "completion_date": "2022-03-28",
      "has_results": false,
      "last_update_posted_date": "2022-11-23",
      "last_synced_at": "2026-11-10T07:50:20.490Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04035239"
    },
    {
      "nct_id": "NCT03505567",
      "title": "Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glaucoma",
        "Retinal Disease",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "KOWA OCT Bi-µ",
          "type": "DEVICE"
        },
        {
          "name": "Optovue iVue 100",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Kowa Research Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-04-21",
      "completion_date": "2018-09-01",
      "has_results": false,
      "last_update_posted_date": "2018-09-10",
      "last_synced_at": "2026-11-10T07:50:20.490Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03505567"
    },
    {
      "nct_id": "NCT02288559",
      "title": "A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "Sham",
          "type": "OTHER"
        },
        {
          "name": "Lampalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2015-03-30",
      "completion_date": "2017-06-02",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-11-10T07:50:20.490Z",
      "location_count": 36,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02288559"
    },
    {
      "nct_id": "NCT00233324",
      "title": "Surfactant Positive Airway Pressure and Pulse Oximetry Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infant, Newborn, Diseases",
        "Other Preterm Infants",
        "Infant, Small for Gestational Age",
        "Premature Birth",
        "Bronchopulmonary Dysplasia",
        "Retinopathy of Prematurity"
      ],
      "interventions": [
        {
          "name": "Surfactant",
          "type": "DRUG"
        },
        {
          "name": "Continuous Positive Airway Pressure (CPAP)",
          "type": "DEVICE"
        },
        {
          "name": "Supplemental oxygen with target saturation of 85 to 89%",
          "type": "DRUG"
        },
        {
          "name": "Supplemental oxygen with target saturation of 91 to 95%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "NICHD Neonatal Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Weeks",
        "maximum_age": "27 Weeks",
        "sex": "ALL",
        "summary": "24 Weeks to 27 Weeks"
      },
      "enrollment_count": 1316,
      "start_date": "2005-02",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2019-04-18",
      "last_synced_at": "2026-11-10T07:50:20.490Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • San Diego, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00233324"
    },
    {
      "nct_id": "NCT07922460",
      "title": "Anti-VEGF Versus Prompt Laser or Observation for Proliferative Sickle Cell Retinopathy (ALPS)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Proliferative Sickle Cell Retinopathy"
      ],
      "interventions": [
        {
          "name": "Faricimab Injection for stage 3 or stage 4 Proliferative sickle cell eyes",
          "type": "DRUG"
        },
        {
          "name": "Vitrectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Laser photocoagulation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Illinois Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-12-01",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-10T07:50:20.490Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07922460"
    },
    {
      "nct_id": "NCT03316560",
      "title": "Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "X-Linked Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "rAAV2tYF-GRK1-RPGR",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Beacon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "6 Years to 50 Years · Male only"
      },
      "enrollment_count": 29,
      "start_date": "2018-04-16",
      "completion_date": "2025-03",
      "has_results": false,
      "last_update_posted_date": "2024-05-20",
      "last_synced_at": "2026-11-10T07:50:20.490Z",
      "location_count": 4,
      "location_summary": "Durham, North Carolina • Cincinnati, Ohio • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03316560"
    }
  ]
}